

Justin Stebbing

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2930229/publications.pdf>

Version: 2024-02-01

227
papers

9,464
citations

57758

44
h-index

45317

90
g-index

243
all docs

243
docs citations

243
times ranked

17150
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurolymphomatosis of multifocal peripheral nerve involvement: a case report. <i>Annals of Palliative Medicine</i> , 2022, 11, 2529-2537.	1.2	1
2	Novel immunotherapeutic drugs for the treatment of lung cancer. <i>Current Opinion in Oncology</i> , 2022, 34, 89-94.	2.4	9
3	Risk and Incidence of Infection with Bevacizumab in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis. <i>Oncology Research and Treatment</i> , 2022, 45, 281-290.	1.2	3
4	Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report. <i>BMC Pulmonary Medicine</i> , 2022, 22, 54.	2.0	0
5	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	3.7	5
6	Developments in paediatric cancer care throughout the COVID-19 pandemic: Lessons from China. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 20, 100398.	2.9	0
7	Alternative splicing events in tumor immune infiltration in renal clear cell carcinomas. <i>Cancer Gene Therapy</i> , 2022, 29, 1418-1428.	4.6	2
8	PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38MAPK signalling. <i>Oncogene</i> , 2022, 41, 2749-2763.	5.9	14
9	Targeting ALK Rearrangements in NSCLC: Current State of the Art. <i>Frontiers in Oncology</i> , 2022, 12, 863461.	2.8	15
10	Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID-19 Study. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 650-658.	2.6	9
11	Identification of an immune gene-associated prognostic signature in patients with bladder cancer. <i>Cancer Gene Therapy</i> , 2022, 29, 494-504.	4.6	6
12	Baricitinib as the treatment of choice for hospitalised individuals with COVID-19. <i>EClinicalMedicine</i> , 2022, 49, 101493.	7.1	5
13	The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19. <i>Vaccines</i> , 2022, 10, 951.	4.4	8
14	A novel platform for attenuating immune hyperactivity using EXO-CD24 in COVID-19 and beyond. <i>EMBO Molecular Medicine</i> , 2022, 14, .	6.9	27
15	Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2021, 274, e1-e9.	4.2	20
16	Is asthma protective against COVID-19? <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 866-868.	5.7	117
17	The Emergence of Baricitinib: A Story of Tortoises Versus Hares. <i>Clinical Infectious Diseases</i> , 2021, 72, 1251-1252.	5.8	5
18	The LMTK-family of kinases: Emerging important players in cell physiology and pathogenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 165372.	3.8	15

#	ARTICLE	IF	CITATIONS
19	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. Journal of the National Cancer Institute, 2021, 113, 443-452.	6.3	22
20	<scp>COVID</scp> and the risk to cancer patients in China. International Journal of Cancer, 2021, 148, 265-266.	5.1	3
21	SCIRT lncRNA Restrains Tumorigenesis by Opposing Transcriptional Programs of Tumor-Initiating Cells. Cancer Research, 2021, 81, 580-593.	0.9	18
22	JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Science Advances, 2021, 7, .	10.3	176
23	SARS-CoV-2 (COVID-19) superspreader events. Journal of Infection, 2021, 82, 36-40.	3.3	114
24	Reducing transmission of SARS-CoV-2 with intranasal prophylaxis. EBioMedicine, 2021, 63, 103170.	6.1	3
25	Clinical Characteristics and Outcomes of COVID-19â€“Infected Cancer Patients: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2021, 113, 371-380.	6.3	153
26	Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. Journal of Allergy and Clinical Immunology, 2021, 147, 107-111.	2.9	140
27	Asthma phenotypes, comorbidities, and disease activity in COVIDâ€“19: The need of risk stratification. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 955-956.	5.7	4
28	Response to Cottu, Bozec, Basse, and Paoletti. Journal of the National Cancer Institute, 2021, 113, 344-345.	6.3	0
29	LMTK3 inhibition affects microtubule stability. Molecular Cancer, 2021, 20, 53.	19.2	6
30	What is the intermediate host species of SARS-CoV-2?. Future Virology, 2021, 16, 153-156.	1.8	8
31	Immunogenicity of the <scp>BNT162b2</scp> vaccine in frail or disabled nursing home residents: <scp>COVIDâ€“19</scp> study. Journal of the American Geriatrics Society, 2021, 69, 1441-1447.	2.6	69
32	Profiling circulating tumour cells and cell free DNA together in metastatic colon cancer. British Journal of Cancer, 2021, 125, 907-908.	6.4	0
33	Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC. OncoTargets and Therapy, 2021, Volume 14, 3409-3415.	2.0	4
34	Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients. Breast Cancer Research and Treatment, 2021, 188, 465-476.	2.5	1
35	Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. Breast Cancer Research and Treatment, 2021, 188, 631-640.	2.5	11
36	Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals. Annals of the Rheumatic Diseases, 2021, 80, 1245-1246.	0.9	10

#	ARTICLE	IF	CITATIONS
37	First-Line Treatment Options for PD-L1“Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 657545.	2.8	6
38	EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes. <i>Frontiers in Oncology</i> , 2021, 11, 680804.	2.8	19
39	Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 2752-2758.	2.6	25
40	Immunotherapy-Related Cystitis: Case Report and Review of the Literature. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4321-4328.	2.0	12
41	JAK Inhibitors “More Than Just Glucocorticoids. <i>New England Journal of Medicine</i> , 2021, 385, 463-465.	27.0	15
42	Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1349-1351.	10.7	28
43	Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?. <i>Translational Lung Cancer Research</i> , 2021, 10, 3858-3860.	2.8	1
44	A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers. <i>Frontiers in Immunology</i> , 2021, 12, 762598.	4.8	39
45	Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 754768.	2.8	13
46	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. <i>JCO Precision Oncology</i> , 2021, 5, 1768-1776.	3.0	12
47	A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 778637.	2.8	2
48	The Use of Transdermal Estrogen in Castrate-resistant, Steroid-refractory Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e217-e223.	1.9	3
49	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. <i>Oncogene</i> , 2020, 39, 1846-1859.	5.9	29
50	A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1505-1511.	2.4	39
51	Sports balls as potential SARS-CoV-2 transmission vectors. <i>Public Health in Practice</i> , 2020, 1, 100029.	1.5	4
52	Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 549168.	2.8	9
53	Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury. <i>Cell Reports Medicine</i> , 2020, 1, 100145.	6.5	12
54	The structure-function relationship of oncogenic LMTK3. <i>Science Advances</i> , 2020, 6, .	10.3	18

#	ARTICLE	IF	CITATIONS
55	Reply to letter to the editor: baricitinib and toxicity is a rare occurrence. Expert Opinion on Drug Safety, 2020, 19, 1371-1372.	2.4	1
56	A cell-cycle signature classifier for pan-cancer analysis. Oncogene, 2020, 39, 6041-6042.	5.9	8
57	CNS penetration of potential anti-COVID-19 drugs. Journal of Neurology, 2020, 267, 1880-1882.	3.6	37
58	Mechanism of baricitinib supports artificial intelligenceâ€predicted testing in <scp>COVID</scp> â€19 patients. EMBO Molecular Medicine, 2020, 12, e12697.	6.9	229
59	Lessons to Europe from China for cancer treatment during the COVID-19 pandemic. British Journal of Cancer, 2020, 123, 7-8.	6.4	3
60	A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. Oncoimmunology, 2020, 9, 1781333.	4.6	34
61	What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials. Med, 2020, 1, 9-10.	4.4	5
62	COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infectious Diseases, The, 2020, 20, 400-402.	9.1	915
63	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. Journal of Clinical Oncology, 2020, 38, 1070-1080.	1.6	19
64	Managing patients with cancer in the COVID-19 era. European Journal of Cancer, 2020, 132, 5-7.	2.8	16
65	Baricitinib for COVID-19: a suitable treatment? â€ Authors' reply. Lancet Infectious Diseases, The, 2020, 20, 1013-1014.	9.1	55
66	Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet, The, 2020, 395, e30-e31.	13.7	1,147
67	805â€...Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours. , 2020, 8, A854-A854.		3
68	PIK3CÎ expression by fibroblasts promotes triple-negative breast cancer progression. Journal of Clinical Investigation, 2020, 130, 3188-3204.	8.2	33
69	Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping. Communications Biology, 2019, 2, 315.	4.4	71
70	Endocrine Resistance in Hormone Receptor Positive Breast Cancerâ€From Mechanism to Therapy. Frontiers in Endocrinology, 2019, 10, 245.	3.5	150
71	SSB1/SSB2 Proteins Safeguard B Cell Development by Protecting the Genomes of B Cell Precursors. Journal of Immunology, 2019, 202, 3423-3433.	0.8	6
72	Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clinical Cancer Research, 2019, 25, 4255-4263.	7.0	281

#	ARTICLE	IF	CITATIONS
73	Thermosensitive Liposome-Mediated Drug Delivery in Chemotherapy: Mathematical Modelling for Spatio-temporal Drug Distribution and Model-Based Optimisation. <i>Pharmaceutics</i> , 2019, 11, 637.	4.5	10
74	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	4.4	200
75	Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 454-458.	1.1	12
76	A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 505-514.	2.3	32
77	Image-guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours. <i>Journal of Controlled Release</i> , 2018, 280, 87-98.	9.9	66
78	LMTK3 confers chemo-resistance in breast cancer. <i>Oncogene</i> , 2018, 37, 3113-3130.	5.9	31
79	Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 531-541.	2.4	5
80	Efficacy and safety of the trastuzumab biosimilar candidate CT-P6. <i>Future Oncology</i> , 2018, 14, 1909-1919.	2.4	9
81	Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. <i>Oncolimmunology</i> , 2018, 7, e1396403.	4.6	60
82	Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.5	19
83	Human NK Cells Develop an Exhaustion Phenotype During Polar Degranulation at the <i>Aspergillus fumigatus</i> Hyphal Synapse. <i>Frontiers in Immunology</i> , 2018, 9, 2344.	4.8	16
84	Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 275-281.	1.4	47
85	Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans. <i>Oncotarget</i> , 2018, 9, 17589-17596.	1.8	4
86	Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma. <i>Molecular Cancer</i> , 2018, 17, 132.	19.2	67
87	TGF- β 2 induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. <i>Nature Communications</i> , 2018, 9, 1845.	12.8	101
88	The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of indolent stage IV disease (Stage IV indolent).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1019-1019.	1.6	3
89	Pharmacokinetics of CT-P6 and reference trastuzumab by clinical factors in patients with HER2 positive early-stage breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 591-591.	1.6	2
90	The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas. <i>Oncotarget</i> , 2018, 9, 11371-11376.	1.8	2

#	ARTICLE	IF	CITATIONS
91	Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?. Oncotarget, 2018, 9, 9456-9467.	1.8	10
92	Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments. Oncotarget, 2018, 9, 12805-12811.	1.8	2
93	Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. Oncotarget, 2018, 9, 19006-19013.	1.8	116
94	Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy. Oncotarget, 2018, 9, 6007-6014.	1.8	1
95	Enhanced Sensitivity of Lymphoid Cells to Ethanol ADH Acetaldehyde Toxicity; Implications for GDEPT and Adoptive T Cell Therapy. Current Pharmacogenomics and Personalized Medicine, 2018, 16, 118-123.	0.2	0
96	Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Clinical Cancer Research, 2017, 23, 88-96.	7.0	186
97	The relationship between ethnicity, social deprivation and late presentation of colorectal cancer. Cancer Epidemiology, 2017, 47, 88-93.	1.9	21
98	Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors. Cell Reports, 2017, 18, 1687-1698.	6.4	15
99	Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR. Nucleic Acids Research, 2017, 45, gkx022.	14.5	15
100	The need for multidisciplinary in specialist training to optimize future patient care. Nature Reviews Clinical Oncology, 2017, 14, 508-517.	27.6	5
101	CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncology, The, 2017, 18, 917-928.	10.7	93
102	The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer. Molecular Cancer Therapeutics, 2017, 16, 2246-2256.	4.1	24
103	The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 338-346.	3.7	299
104	Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).. Journal of Clinical Oncology, 2017, 35, 510-510.	1.6	10
105	Surgery in combination with peptide receptor radionuclide therapy is effective in metastatic neuroendocrine tumors and is definable by blood gene transcript analysis.. Journal of Clinical Oncology, 2017, 35, e15697-e15697.	1.6	0
106	Garlic: a stake through the heart of cancer?. Lancet Oncology, The, 2016, 17, 879-880.	10.7	7
107	Turmeric: a spice for life?. Lancet Oncology, The, 2016, 17, 1639.	10.7	2
108	Gene of the month: Axl. Journal of Clinical Pathology, 2016, 69, 391-397.	2.0	30

#	ARTICLE	IF	CITATIONS
109	Aloe vera, a natural cancer soother?. Lancet Oncology, The, 2016, 17, 421.	10.7	8
110	Proteome-wide dataset supporting functional study of tyrosine kinases in breast cancer. Data in Brief, 2016, 7, 740-746.	1.0	3
111	Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. British Journal of Cancer, 2016, 115, 789-796.	6.4	56
112	miR-155 controls cancer cell migration through MARK4 regulation. EMBO Reports, 2016, 17, 570-584.	4.5	97
113	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogenic primary and metastatic lung cancer: Implications for immunotherapy. OncoImmunology, 2016, 5, e1213934.	4.6	65
114	Investigating miRNA-mRNA regulatory networks using crosslinking immunoprecipitation methods for biomarker and target discovery in cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1155-1162.	3.1	9
115	Strategies in functional proteomics: Unveiling the pathways to precision oncology. Cancer Letters, 2016, 382, 86-94.	7.2	7
116	Melatonin: resetting the clock of cancer progression?. Lancet Oncology, The, 2016, 17, 23-24.	10.7	13
117	LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5. Cancer Letters, 2016, 372, 137-146.	7.2	30
118	TP53 regulates miRNA association with AGO2 to remodel the miRNA-mRNA interaction network. Genome Research, 2016, 26, 331-341.	5.5	51
119	Single-cell sequencing in cancer research. Expert Review of Molecular Diagnostics, 2016, 16, 1-5.	3.1	8
120	Spatially resolved profiling of colorectal cancer lipid biochemistry via DESI imaging mass spectrometry to reveal morphology-dependent alterations in fatty acid metabolism.. Journal of Clinical Oncology, 2016, 34, e15104-e15104.	1.6	4
121	Programmed cell death (PD-1) ligands expression in gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs): relationship with angiogenesis and clinical outcome.. Journal of Clinical Oncology, 2016, 34, e15658-e15658.	1.6	3
122	ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation. Oncotarget, 2016, 7, 27599-27612.	1.8	21
123	Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. Oncotarget, 2016, 7, 28556-28569.	1.8	19
124	MicroRNAs associated with small bowel neuroendocrine tumors and their metastases.. Journal of Clinical Oncology, 2016, 34, 11598-11598.	1.6	0
125	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogenic primary and metastatic lung cancer (LC): Implications for immunotherapy.. Journal of Clinical Oncology, 2016, 34, 11601-11601.	1.6	1
126	Abstract 185: Role of phosphorylation in Lmtk3 activation and its contribution in breast cancer progression. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
127	Abstract LB-339: Mutation analysis of cell-free DNA captures heterogeneity of individual circulating tumor cells in metastatic breast cancer. , 2016, , .		0
128	HOT mutation screening in human glioblastomas. Future Science OA, 2015, 1, .	1.9	1
129	Mammosphere Formation Assay from Human Breast Cancer Tissues and Cell Lines. Journal of Visualized Experiments, 2015, , .	0.3	89
130	Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptorâ€“Positive Metastatic Breast Cancer. Clinical Chemistry, 2015, 61, 974-982.	3.2	155
131	LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer. Cell Reports, 2015, 12, 837-849.	6.4	21
132	Black cohosh, hot flushes, and breast cancer. Lancet Oncology, The, 2015, 16, 137-138.	10.7	12
133	The role of TP53 in miRNA loading onto AGO2 and in remodelling the miRNAâ€“mRNA interaction network. Lancet, The, 2015, 385, S15.	13.7	23
134	microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. European Journal of Cancer, 2015, 51, 1389-1404.	2.8	94
135	Genetic variants and response to cancer treatments. Cancer, 2015, 121, 1735-1736.	4.1	0
136	Artemisia: a divine dart against cancer?. Lancet Oncology, The, 2015, 16, 759-760.	10.7	0
137	Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics. Molecular and Cellular Proteomics, 2015, 14, 2479-2492.	3.8	17
138	The germline of the malaria mosquito produces abundant miRNAs, endo-siRNAs, piRNAs and 29-nt small RNAs. BMC Genomics, 2015, 16, 100.	2.8	44
139	Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis. American Journal of Gastroenterology, 2015, 110, 768-769.	0.4	2
140	Probiotics and cancer: ready for meal time?. Lancet Oncology, The, 2015, 16, 371-372.	10.7	0
141	Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. Lancet, The, 2015, 385, S37.	13.7	54
142	Cannabis and cancer: reality or pipe dream?. Lancet Oncology, The, 2015, 16, 1291-1292.	10.7	7
143	Gene of the month: <i>NANOG</i>. Journal of Clinical Pathology, 2015, 68, 763-765.	2.0	13
144	Noncoding RNAs and the control of signalling via nuclear receptor regulation in health and disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 529-543.	4.7	13

#	ARTICLE	IF	CITATIONS
145	Abstract P3-06-31: Patient-derived xenografts accurately predict patient response in breast cancer patients. , 2015, , .		1
146	The many-faced KSR1: a tumor suppressor in breast cancer. Oncoscience, 2015, 2, 669-670.	2.2	0
147	The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated Induction of Integrin $\beta 1$. Science Signaling, 2014, 7, ra58.	3.6	32
148	Whole Genome Sequence Analysis Suggests Intratumoral Heterogeneity in Dissemination of Breast Cancer to Lymph Nodes. PLoS ONE, 2014, 9, e115346.	2.5	15
149	Reply to S.E. Krown et al. Journal of Clinical Oncology, 2014, 32, 2514-2515.	1.6	3
150	Hyperthermia in cancer: is it coming of age?. Lancet Oncology, The, 2014, 15, 565-566.	10.7	20
151	MicroRNAs Cooperatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression. Gastroenterology, 2014, 146, 268-277.e18.	1.3	141
152	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncology, The, 2014, 15, 406-414.	10.7	703
153	Uncaria tomentosa, the cat's whiskers or claws?. Lancet Oncology, The, 2014, 15, 1299-1300.	10.7	2
154	Electrotherapy: enlightening modern medicine. Lancet Oncology, The, 2014, 15, 1060-1061.	10.7	2
155	Cancer: Where were we, where are we, where are we going. Medico-Legal Journal, 2014, 82, 57-66.	0.5	1
156	Crystals and cancer: good vibrations or bad intentions?. Lancet Oncology, The, 2014, 15, 263-264.	10.7	0
157	Patient-derived xenografts for individualized care in advanced sarcoma. Cancer, 2014, 120, 2006-2015.	4.1	154
158	MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma. PLoS ONE, 2014, 9, e85935.	2.5	26
159	Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets. PLoS ONE, 2014, 9, e90948.	2.5	53
160	Circulating free DNA in the management of breast cancer. Annals of Translational Medicine, 2014, 2, 3.	1.7	23
161	Abstract 1606: Global mapping of tyrosine kinase signalling in breast cancer by combined use of RNAi and SILAC quantitative proteomics. , 2014, , .		0
162	Abstract 4213: Evaluation of LMTK3 expression and tumor phenotype in estrogen-dependent colorectal cancer. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
163	Abstract 5268: The expression of lemur tyrosine kinase-3 in high grade pediatric tumors. , 2014, , .		0
164	Abstract 1617: Quantification of pancreatic cancer proteome & phosphorylome: Indicates molecular events likely contributing to cancer & activation status of drug targets. , 2014, , .		0
165	Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Research, 2014, 34, 1531-5.	1.1	44
166	Chocolate: delicious beauty or harmful beast?. Lancet Oncology, The, 2013, 14, 457-458.	10.7	8
167	Milk thistle: early seeds of potential. Lancet Oncology, The, 2013, 14, 929-930.	10.7	23
168	Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States. Molecular Cancer Therapeutics, 2013, 12, 2261-2272.	4.1	19
169	The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study. PLoS ONE, 2013, 8, e62543.	2.5	32
170	Abstract 3794: The role of LMTK3 in breast cancer cell growth and invasion.. , 2013, , .		0
171	An overview of drug development for metastatic breast cancer. British Journal of Nursing, 2012, 21, S18-S22.	0.7	12
172	Ginger: the root of cancer therapy?. Lancet Oncology, The, 2012, 13, 235-236.	10.7	13
173	LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Research and Treatment, 2012, 132, 537-544.	2.5	35
174	Abstract 2670: Genetic variants in human epidermal growth factor receptor (HER) family gene predict tumor recurrence in breast cancer. , 2012, , .		1
175	LMTK3 polymorphism in patients with metastatic colon cancer.. Journal of Clinical Oncology, 2012, 30, 471-471.	1.6	6
176	Use of genetic variants of LMTK3 to predict tumor recurrence in female localized gastric adenocarcinoma.. Journal of Clinical Oncology, 2012, 30, 63-63.	1.6	1
177	Association of gender-related tumor recurrence with a polymorphic variant of LMTK3 in stage II and III colon cancer.. Journal of Clinical Oncology, 2012, 30, 454-454.	1.6	3
178	Abstract LB-8: Liquid chromatography - mass spectrometry proteomics to monitor the activity of multiple phosphorylation signaling pathways in cancer. , 2012, , .		0
179	Abstract 64: Identification of novel kinases involved in Estrogen receptor- $\hat{1}\pm$ (ER $\hat{1}\pm$) signalling and the development of endocrine resistance in breast cancer. , 2012, , .		0
180	Antioxidants and cancer. Lancet Oncology, The, 2011, 12, 996.	10.7	16

#	ARTICLE	IF	CITATIONS
181	HBV and lymphoma: HIV matters. <i>Aids</i> , 2011, 25, 274-275.	2.2	0
182	Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. <i>Blood</i> , 2011, 118, 271-275.	1.4	69
183	Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. <i>Nature Medicine</i> , 2011, 17, 715-719.	30.7	118
184	The anti-tumor effects of human immunodeficiency virus protease inhibitors: Ready for real time?. <i>International Journal of Cancer</i> , 2011, 128, 1-2.	5.1	2
185	Epidermal growth factor receptor status in early stage breast cancer is associated with cellular proliferation but not cross-talk. <i>Journal of Clinical Pathology</i> , 2011, 64, 829-831.	2.0	5
186	A Meta-analysis of Transient Elastography for the Detection of Hepatic Fibrosis. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 214-219.	2.2	185
187	No evidence for a polyomavirus association or aetiology in AIDS-associated nonsmall cell lung cancer. <i>Aids</i> , 2010, 24, 1221-1223.	2.2	7
188	Circulating sphingosine-1-phosphate inversely correlates with chemotherapy-induced weight gain during early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 543-549.	2.5	6
189	Kinases as targets in the treatment of solid tumors. <i>Cellular Signalling</i> , 2010, 22, 984-1002.	3.6	88
190	Primary Esophageal Carcinoma in the Era of Highly Active Antiretroviral Therapy. <i>Archives of Internal Medicine</i> , 2010, 170, 203.	3.8	17
191	Reply to Z.S. Lalmahomed et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e290-e290.	1.6	1
192	Abstract LB-226: Identification of novel kinases modulating ER: new therapeutic targets in breast cancer. , 2010, , .		0
193	The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. <i>Lung Cancer</i> , 2009, 63, 94-97.	2.0	134
194	BIK (Bcl2-Interacting Killer) CpG Methylation Status in Multiple Myeloma Patients: a Potential Predictor of Relapsed/Refractory Disease.. <i>Blood</i> , 2009, 114, 2397-2397.	1.4	0
195	Cardiotoxicity and anthracyclines. <i>Breast Cancer Research and Treatment</i> , 2008, 107, 451-453.	2.5	7
196	Cancer vaccines: Clinical development challenges and proposed regulatory approaches for patient access to promising treatments. <i>Cancer</i> , 2008, 112, 955-961.	4.1	6
197	The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. <i>Cancer</i> , 2008, 113, 1489-1495.	4.1	14
198	HIV-associated multicentric Castleman's disease. <i>American Journal of Hematology</i> , 2008, 83, 498-503.	4.1	74

#	ARTICLE	IF	CITATIONS
199	Use of Antidepressants and Risk of Cancer in Individuals Infected With HIV. <i>Journal of Clinical Oncology</i> , 2008, 26, 2305-2310.	1.6	6
200	Methylation Status of SMURF2 and Correlation with Clinical Parameters in Patients with Multiple Myeloma. <i>Blood</i> , 2008, 112, 4472-4472.	1.4	0
201	Snk/Plk2 Methylation Is a Frequent Event in Patients with Multiple Myeloma. <i>Blood</i> , 2008, 112, 4479-4479.	1.4	0
202	Prognostic Significance of Immune Subset Measurement in Individuals With AIDS-Associated Kaposi's Sarcoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2230-2235.	1.6	10
203	Virological failure and subsequent resistance profiles in individuals exposed to atazanavir. <i>Aids</i> , 2007, 21, 1826-1828.	2.2	6
204	Translational review of AIDS-related Kaposi's sarcoma. <i>Update on Cancer Therapeutics</i> , 2007, 2, 53-60.	0.4	0
205	Efficacy and safety of first or second line irinotecan, cisplatin, and mitomycin in mesothelioma. <i>Cancer</i> , 2007, 109, 93-99.	4.1	45
206	AIDS-related cancers, Part II: Systemic and cerebral lymphomas. <i>Community Oncology</i> , 2006, 3, 34-41.	0.2	0
207	AIDS associated malignancies. <i>Update on Cancer Therapeutics</i> , 2006, 1, 221-234.	0.4	0
208	Opposing roles of dendritic cell subsets in HIV-1 infection. <i>Blood</i> , 2006, 108, 1785-1786.	1.4	1
209	New therapies for hepatitis infection. <i>Future Virology</i> , 2006, 1, 533-535.	1.8	0
210	Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 335-341.	2.4	17
211	Hepatitis C Virus Infection in HIV Type 1-Infected Individuals Does Not Accelerate a Decrease in the CD4+ Cell Count but Does Increase the Likelihood of AIDS-Defining Events. <i>Clinical Infectious Diseases</i> , 2005, 41, 906-911.	5.8	35
212	Paclitaxel for AIDS-associated Kaposi's sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 215-219.	2.4	21
213	AIDS-related cancers, Part I: Kaposi's sarcoma and cervical cancer. <i>Community Oncology</i> , 2005, 2, 507-511.	0.2	0
214	The Rationale and Development of New Drugs to Treat HIV Infection. <i>Medicinal Chemistry</i> , 2005, 1, 635-642.	1.5	5
215	A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART). <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 501-505.	3.0	15
216	Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patients. <i>Cell Research</i> , 2004, 14, 251-256.	12.0	9

#	ARTICLE	IF	CITATIONS
217	Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma. International Journal of Cancer, 2004, 108, 473-474.	5.1	28
218	The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma. International Journal of Cancer, 2004, 108, 631-633.	5.1	33
219	Kaposi's sarcoma as a model for cancer immunotherapy. Trends in Molecular Medicine, 2004, 10, 187-193.	6.7	8
220	Where Does HIV Live?. New England Journal of Medicine, 2004, 350, 1872-1880.	27.0	137
221	Antibody-targeted MHC complexâ€‘directed expansion of HIV-1â€‘ and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccination. Blood, 2004, 103, 1791-1795.	1.4	18
222	New insights into the immunology and evolution of HIV. Cell Research, 2003, 13, 1-7.	12.0	21
223	All for CD91 and CD91 for all. Journal of Antimicrobial Chemotherapy, 2003, 53, 1-3.	3.0	13
224	The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1â€‘infected â€œtrueâ€‘ long-term nonprogressors. Blood, 2003, 101, 4000-4004.	1.4	54
225	Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor. Blood, 2003, 102, 1806-1814.	1.4	45
226	Bella and the blood sample. BMJ: British Medical Journal, 2003, 327, 497-497.	2.3	0
227	Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcoma. Aids, 2003, 17, 1998-2000.	2.2	8